JPWO2023153471A5 - - Google Patents

Info

Publication number
JPWO2023153471A5
JPWO2023153471A5 JP2023580314A JP2023580314A JPWO2023153471A5 JP WO2023153471 A5 JPWO2023153471 A5 JP WO2023153471A5 JP 2023580314 A JP2023580314 A JP 2023580314A JP 2023580314 A JP2023580314 A JP 2023580314A JP WO2023153471 A5 JPWO2023153471 A5 JP WO2023153471A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
set forth
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580314A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023153471A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/004346 external-priority patent/WO2023153471A1/ja
Publication of JPWO2023153471A1 publication Critical patent/JPWO2023153471A1/ja
Publication of JPWO2023153471A5 publication Critical patent/JPWO2023153471A5/ja
Pending legal-status Critical Current

Links

JP2023580314A 2022-02-09 2023-02-09 Pending JPWO2023153471A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022019051 2022-02-09
PCT/JP2023/004346 WO2023153471A1 (ja) 2022-02-09 2023-02-09 Fcrl1に結合する抗体又は該抗体断片

Publications (2)

Publication Number Publication Date
JPWO2023153471A1 JPWO2023153471A1 (https=) 2023-08-17
JPWO2023153471A5 true JPWO2023153471A5 (https=) 2026-02-17

Family

ID=87564452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580314A Pending JPWO2023153471A1 (https=) 2022-02-09 2023-02-09

Country Status (10)

Country Link
US (1) US20250382371A1 (https=)
EP (1) EP4477752A4 (https=)
JP (1) JPWO2023153471A1 (https=)
KR (1) KR20240141760A (https=)
CN (1) CN118679260A (https=)
AU (1) AU2023218150A1 (https=)
CA (1) CA3252263A1 (https=)
MX (1) MX2024009817A (https=)
TW (1) TW202342518A (https=)
WO (1) WO2023153471A1 (https=)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US160735A (en) 1875-03-09 Improvement in sash-holders
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
JP2564268B2 (ja) 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α2→3シアリルトランスフェラーゼ
SG49117A1 (en) 1993-03-29 1998-05-18 Kyowa Hakko Kogyo Kk Alfa -1, 3-fucosyltransferase
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素-5受体α链的抗体
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
EP1696963A2 (en) 2003-12-24 2006-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
US20080131433A1 (en) 2004-09-27 2008-06-05 The Uab Research Foundation Fc Receptor Homolog Antibodies And Uses Thereof
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
BRPI1010759B1 (pt) 2009-06-11 2019-07-16 Inter-University Research Institute Corporation Research Organization Of Information And Systems Método para produzir uma proteína de interesse ou para obter uma suspensão de células de mamíferos capaz de produzir uma proteína de interesse, bem como vetor de expressão de proteína
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
LT3129406T (lt) 2014-04-11 2019-04-10 Medimmune, Llc Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.

Similar Documents

Publication Publication Date Title
JP2024050548A (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
US12247075B2 (en) BTN3A binding proteins and uses thereof
EP2050764A1 (en) Novel polyvalent bispecific antibody format and uses thereof
WO2018023976A1 (zh) 抗人ifnar1的抗体及其用途
JP2023509212A (ja) 新型ポリペプチド複合物
EP2928919A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP7538131B2 (ja) 抗cd79b抗体、その抗原結合フラグメントおよびそれらの医薬用途
CN114591434B (zh) 抗Siglec15抗体及其制备方法和用途
JP2021530244A5 (https=)
JP2024001073A5 (https=)
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
JP7821161B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
CN119053622A (zh) 一种抗ceacam5和ceacam6抗体及其应用
JPWO2020023644A5 (https=)
JPWO2023153471A5 (https=)
WO2025213712A1 (zh) 基于ai从头设计筛选合成的her2蛋白特异性结合抗体及其应用
JP7641292B2 (ja) 抗cd19抗体、その使用方法及び製造方法
CN115947855A (zh) 抗cd24抗体的制备及其用途
CN118667002A (zh) 抗cd27单克隆抗体及其应用
RU2024122660A (ru) Антитело или его фрагмент, которое связывается с fcrl1
JP7821159B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
JPWO2020102555A5 (https=)
TWI869740B (zh) 一種體外檢測sTNFR2蛋白濃度的方法及其檢測試劑和檢測試劑盒
TW202413405A (zh) 抗體、其抗原結合片段及其藥物用途
CN121532424A (zh) Btn3a结合蛋白及其医药用途